Generated by AI
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines that correct abnormal gene expression. Foghorn Therapeutics Inc. uses its proprietary Gene Traffic Control platform to study the chromatin regulatory system, a core mechanism that influences how genes are activated or silenced in cells. Its current programs are centered on oncology, with efforts directed at genetically defined cancers and other serious diseases linked to chromatin-driven dependencies. The company’s research and development activities include precision therapeutics designed to identify and validate drug targets within this regulatory network, supporting the creation of targeted treatments for hard-to-address diseases. Headquartered in Watertown, Massachusetts, Foghorn Therapeutics Inc. plays a specialized role in the biotechnology market as a developer of novel, mechanism-based therapies.
Website99 Coolidge Avenue
Watertown, MA, 02472
United States
The latest articles about FHTX.
WATERTOWN, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a biotechnology company pioneering a new class of medicines against challenging targets in oncology and immunology & inflammation, today announced that management will participate in the Guggenheim Third Annual Healthcare Innovation Conference, Stifel 2026 Healthcare Conference, and Jefferies 2026 London Healthcare Conference. Guggenheim Third Annual Healthcare Innovation Conference Fireside Chat: Tues
Summary of Oct 1's posts. Generated by AI.
Summary of Feb 9's posts. Generated by AI.
Summary of Oct 1's posts. Generated by AI.
Investors talking about FHTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.